Leveraging on past investment in understanding the immunology of COVID-19 – the South African experience

Authors

  • Thandeka Moyo-Gwete 1.National Institute for Communicable Diseases (NICD), National Health Laboratory Service (NHLS), Johannesburg, South Africa; 2.SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa https://orcid.org/0000-0002-4269-9281
  • Penny L. Moore 1.National Institute for Communicable Diseases (NICD), National Health Laboratory Service (NHLS), Johannesburg, South Africa; 2.SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 3.Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; 4.Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa https://orcid.org/0000-0001-8719-4028

DOI:

https://doi.org/10.17159/sajs.2022/13171

Keywords:

HIV, SARS-CoV-2, vaccine research, immunology, virology

Downloads

Published

2022-05-31

How to Cite

Moyo-Gwete, T., & Moore, P. L. (2022). Leveraging on past investment in understanding the immunology of COVID-19 – the South African experience. South African Journal of Science, 118(5/6). https://doi.org/10.17159/sajs.2022/13171

Issue

Vol. 118 No. 5/6 (2022)

Section

Commentary

License

Creative Commons License
All articles are published under a Creative Commons Attribution 4.0 International Licence

Copyright is retained by the authors. Readers are welcome to reproduce, share and adapt the content without permission provided the source is attributed.

Disclaimer: The publisher and editors accept no responsibility for statements made by the authors

Funding data